Endostatin, the proteolytic fragment of collagen XVIII, induces vasorelaxation.
Collagen XVIII is an important component of the extracellular matrix and is expressed in basement membranes. Its degradation results in the generation of endostatin claimed to possess antiangiogenic activity. To date, only limited knowledge exists with regard to the cellular signaling of this molecule. We show in single-cell measurements using the Ca2+ indicator fura-2 acetoxy methylester (fura-2 AM) and the nitric oxide (NO) indicator 4,5-diaminofluorescein diacetate that application of endostatin (ES) (5 pmol/L, 100 ng/mL) induced Ca2+ spikes and an increase of NO production in human and murine endothelial cells. The NO response was independent of an increase in cytosolic Ca2+ and blocked by the endothelial NO synthase (eNOS) inhibitor NG-nitro-L-arginine methyl ester and by incubation with pertussis toxin known to inhibit G(i/o) proteins. The physiological relevance of this novel signaling pathway of ES was assessed with isometric force measurements in large and small arteries of mouse. Physiological concentrations of ES were found to decrease vascular tone in an endothelium-dependent manner. This occurred via an Arg-Gly-Asp (RGD) peptide-independent pathway through activation of G(i/o) proteins, phosphatidylinositol 3-kinase, Akt, and eNOS. We conclude that the proteolytic matrix fragment ES is a prominent vasorelaxing agent. Because ES is constantly released into the blood, it is a novel regulator of blood pressure and, therefore, represents an interesting pharmacological target.
Institute of Physiology I, University of Bonn, Argelanderstr. 2a, 53115 Bonn, Germany.
D
D
Wenzel
A
A
Schmidt
K
K
Reimann
J
J
Hescheler
G
G
Pfitzer
W
W
Bloch
B K
BK
Fleischmann
D000818:Animals; D002478:Cells, Cultured; D043169:Endostatins / Q000494:pharmacology*; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D007425:Intracellular Membranes / Q000378:metabolism; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation; D014665:Vasodilator Agents / Q000494:pharmacology*
D043169:Endostatins; D011994:Recombinant Proteins; D014665:Vasodilator Agents; D009569:Nitric Oxide